Mentioned in ?
References in periodicals archive ?
Chen and Australian colleagues enrolled 386 people in their multicenter, double-blind trial (Oral Nicotinamide to Reduce Actinic Cancer [ONTRAC]).
Nicotinamide, an inexpensive, over-the-counter form of vitamin B3, is safe and effective for the chemoprevention of nonmelanoma skin cancer in patients at high risk, based on data from the Australian Oral Nicotinamide to Reduce Actinic Cancer (ONTRAC) study.
Researchers reported the outcomes of the Phase 3 Oral Nicotinamide to Reduce Actinic Cancer (ONTRAC) Study in the Journal of Clinical Oncology this year.